AP Biosciences (ROCO:6945) EBIT: NT$-246.37 Mil (TTM As of Dec. 2025)


ROCO:6945 AP Biosciences Inc ROCO:6945
14 GF Score
Price NT$112.00
! 1 Warning Sign
View Full Analysis

What is AP Biosciences EBIT?

AP Biosciences ROCO:6945 14 EBIT is NT$-246.37 Mil as of Dec. 2025. GuruFocus rates ROCO:6945 with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

AP Biosciences's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was NT$-93.75 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-246.37 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. AP Biosciences's annualized ROC % for the quarter that ended in Dec. 2025 was -249.92%. AP Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -318.87%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. AP Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -2.51%.

AP Biosciences  (ROCO:6945) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

AP Biosciences's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-404.58 * ( 1 - 0% )/( (158.193 + 165.58)/ 2 )
=-404.58/161.8865
=-249.92 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1464.985 - 59.06 - ( 1274.192 - max(0, 71.087 - 1318.819+1274.192))
=158.193

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1365.33 - 28.858 - ( 1170.892 - max(0, 40.798 - 1221.591+1170.892))
=165.58

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

AP Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-375.012/( ( (109.883 + max(-18.876, 0)) + (108.942 + max(16.391, 0)) )/ 2 )
=-375.012/( ( 109.883 + 125.333 )/ 2 )
=-375.012/117.608
=-318.87 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 40.559) - (59.06 + 0 + 0.375)
=-18.876

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 45.537) - (28.858 + 0 + 0.288)
=16.391

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

AP Biosciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-246.366/9807.881
=-2.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AP Biosciences EBIT Related Terms

AP Biosciences EBIT Historical Data

* Premium members only.

The historical data trend for AP Biosciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AP Biosciences EBIT Chart

AP Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial -186.72 -288.54 -338.09 -421.10 -443.34

AP Biosciences Quarterly Data
Dec20 Dec21 Dec22 Jun23 Dec23 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -99.34 -96.34 0.00 -152.61 -93.75

ROCO:6945 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, AP Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AP Biosciences EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AP Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where AP Biosciences's EV-to-EBIT falls into.


ROCO:6945
14GF Score
AP Biosciences Inc ROCO:6945
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AP Biosciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-246.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$-246.37 Mil mean?
AP Biosciences (ROCO:6945) has a EBIT of NT$-246.37 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on AP Biosciences.
Is AP Biosciences' EBIT too high?
AP Biosciences' current EBIT is NT$-246.37 Mil. Overall, AP Biosciences has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does AP Biosciences' EBIT compare to VRTX and REGN?
AP Biosciences' EBIT of NT$-246.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on AP Biosciences. AP Biosciences's current EBIT is NT$-246.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AP Biosciences stock overvalued right now?
AP Biosciences (ROCO:6945) has a current EBIT of NT$-246.37 Mil. The current EBIT is NT$-246.37 Mil. AP Biosciences' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For AP Biosciences (ROCO:6945), the current EBIT is NT$-246.37 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AP Biosciences Business Description

Address No. 3, Park Street, 17th Floor, Taipei, TWN
AP Biosciences Inc is a clinical-stage bispecific antibody new drug research and development company. It has developed a series of antibody and protein lead drugs through a self-designed technology platform for unmet medical needs, focusing on Specific targets associated with diseases to deliver safe, effective and cost-effective medicines.
14GF Score

Get the complete analysis for ROCO:6945

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$112.00
Price